Oxidation of raloxifene to quinoids: Potential toxic pathways via a diquinone methide and o-quinones

Chemical Research in Toxicology

Volumn 17, Issue 7, 2004, Pages 879-888

  Yu, Linning ^a   Liu, Hong ^a   Li, Wenkui ^a,b   Zhang, Fagen ^a,c   Luckie, Connie ^a   Van Breemen, Richard B ^a   Thatcher, Gregory R J ^a   Bolton, Judy L ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Late Stage Developmental Services Covance Inc   (United States)

^c DOW CHEMICAL COMPANY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYRALOXIFENE; DIQUINONE METHIDE; GLUTATHIONE; QUINONE DERIVATIVE; RALOXIFENE; RALOXIFENE 2 QUINONE GLUTATHIONE CONJUGATE; RALOXIFENE DIQUINONE METHIDE GLUTHATIONE CONJUGATE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG TOXICITY; FOOD AND DRUG ADMINISTRATION; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; NONHUMAN; OSTEOPOROSIS; OXIDATION REDUCTION REACTION; RAT; TANDEM MASS SPECTROMETRY; TOXICITY;

ANIMALS; BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GLUTATHIONE; HUMANS; INDOLEQUINONES; MICROSOMES, LIVER; OXIDATION-REDUCTION; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

ANIMALIA;

EID: 3242703146     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0342722     Document Type: Article

References (39)

1. Magriples, U., Naftolin, F., Schwartz, P. E., and Carcangiu, M. L. (1993) High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 11, 485-490.
2. Seoud, M. A., Johnson, J., and Weed, J. C., Jr. (1993) Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet. Gynecol. 82, 165-169.
3. Phillips, D. H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis 22, 839-849.
4. Fisher, B., Constantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., and Cronin, W. M. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel project (NSABP) B-14. J. Natl. Cancer Inst. 86, 527-537.
5. van Leeuwen, F. E., Benraadt, J., Coebergh, J. W., Kiemeney, L. A., Gimbrere, C. H., Otter, R., Schouten, L. J., Damhuis, R. A., Bontenbal, M., Diepenhorst, F. W., van den Belt-Dusebout, A. W., and van Tinteren, H. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343, 448-452.
6. Cook, L. S., Weiss, N. S., Schwartz, S. M., White, E., McKnight, B., Moore, D. E., and Daling, J. R. (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J. Natl. Cancer Inst. 87, 1359-1364.
7. Cuenca, R. E., Giachino, J., Arredondo, M. A., Hempling, R., and Edge, S. B. (1996) Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use. Cancer 77, 2058-2063.
8. Curtis, R. E., Boice, J. D., Jr., Shriner, D. A., Hankey, B. F., and Fraumeni, J. F., Jr. (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 88, 832-834.
9. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. (1992) Genotoxic potential of tamoxifen and analogues in female Fisher F344/n rats, DBA/2 and C57BL/6 and in human MCL-5 cells. Carcinogenesis 13, 2197-2203.
10. Han, X. L., and Liehr, J. G. (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 52, 1360-1363.
11. Randerath, K., Moorthy, B., Mabon, N., and Sriram, P. (1994) Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15, 2087-2094.
12. Hardcastle, I. R., Horton, M. N., Osborne, M. R., Hewer, A., Jarman, M., and Phillips, D. H. (1998) Synthesis and DNA reactivity of α-hydroxylated metabolites of nonsteroidal antiestrogens. Chem. Res. Toxicol. 11, 369-374.
13. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E., and Duffel, M. W. (1998) a-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer. Res. 58, 647-653.
14. Dasaradhi, L., and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxy-tamoxifen. Chem. Res. Toxicol. 10, 189-196.
15. Dehal, S. S., and Kupfer, D. (1996) Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res. 56, 1283-1290.
16. Dehal, S. S., and Kupfer, D. (1999) Cytochrome P450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hy-droxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab. Dispos. 27, 681-688.
17. Beland, F. A., McDaniel, L. P., and Marques, M. M. (1999) Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 20, 471-477.
18. Osborne, M. R., Davis, W., Hewer, A. J., Hardcastle, I. R., and Phillips, D. H. (1999) 4-Hydroxytamoxifen gives DNA adducts by chemical activation, but not in rat liver cells. Chem. Res. Toxicol. 12, 151-158.
19. Marques, M. M., and Beland, F. A. (1997) Identification of tamoxifen-DNA adducts by 4-hydroxytamoxifen quinone methide. Carcinogenesis 18, 1949-1954.
20. Jones, C. D., Jevnikar, M. G., Pike, A. J., Peters, M. K., Black, L. J., Thompson, A. R., Falcone, J. F., and Clemens, J. A. (1984) Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b] thien-3-yl] [4-[2-(1-piperidinyl)ethoxylphenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J. Med. Chem. 27, 1057-1066.
21. Wakeling, A. E., Valcaccia, B., Newboult, E., and Green, L. R. (1984) Nonsteroidal antioestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J. Steroid Biochem. 20, 111-120.
22. Clemens, J. A., Bennett, D. R., Black, L. J., and Jones, C. D. (1983) Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci. 32, 2869-2875.
23. Kelminski, A. (2002) The Study of Tamoxifen and Raloxifene (STAR trial) for the prevention of breast cancer. Hawaii Med. J. 61, 209-210.
24. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914.
25. Thompson, J. A., Malkinson, A. M., Wand, M. D., Mastovich, S. L., Mead, E. W., Schullek, K. M., and Laudenschlager, W. G. (1987) Oxidative metabolism of butylated hydroxytoluene by hepatic and pulmonary microsomes from rats and mice. Drug Metab. Dispos. 15, 833-840.
26. Curtin, D. Y., and Harder, R. J. (1960) Stereochemistry and reactions with hydroxyl ion and with silver oxide of the 2-bromo-4-phenylcyclohexanols and the 1-methyl-2-bromo-4-phenylcyclohexanols. J. Am. Chem. Soc. 82, 2357-2368.
27. Freshney, R. (1987) Culture of Animal Cells: A Manual of Basic Techniques, p 117, Alan R. Liss, Inc., New York.
28. Bolton, J. L., Yu, L., and Thatcher, G. R. J. (2004) Quinoids formed from estrogens and antiestrogens. Methods Enzymol. 378, 110-123.
29. Baillie, T. A., and Davis, M. R. (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319-325.
30. Toader, V., Xu, X., Nicolescu, A., Yu, L., Bolton, J. L., and Thatcher, G. R. (2003) Nitrosation, nitration, and autoxidation of the selective estrogen receptor modulator raloxifene by nitric oxide, peroxynitrite, and reactive nitrogen/oxygen species. Chem. Res. Toxicol. 16, 1264-1276.
31. Morello, K. C., Wurz, G. T., and DeGregorio, M. W. (2003) Pharmacokinetics of selective estrogen receptor modulators. Clin. Pharmacokinet. 42, 361-372.
32. Snyder, K. R., Sparano, N., and Malinowski, J. M. (2000) Raloxifene hydrochloride. Am. J. Health-Syst. Pharm. 57, 1669-1675.
33. Hochner-Celnikier, D. (1999) Pharmacokinetics of raloxifene and its clinical application. Eur. J. Obstet. Gynecol. Reprod. Biol. 85, 23-29.
34. Lim, H. K., Stellingweif, S., Sisenwine, S., and Chan, K. W. (1999) Rapid drug metabolite profiling using fast liquid chromatography, automated multiple-stage mass spectrometry and receptor-binding. J Chromatogr. A 831, 227-241.
35. Fiorelli, G., Picariello, L., Martineti, V., Tonelli, F., and Brandi, M. L. (1999) Estrogen synthesis in human colon cancer epithelial cells. J. Steroid Biochem. Mol. Biol. 71, 223-230.
36. Thompson, D. C., Perera, K., Krol, E. S., and Bolton, J. L. (1995) o-Methoxy-4-alkylphenols that form quinone methides of intermediate reactivity are the most toxic in rat liver slices. Chem. Res. Toxicol. 8, 323-327.
37. Grese, T. A., Cho, S., Finley, D. R., Godfrey, A. G., Jones, C. D., Lugar, C. W., 3rd, Martin, M. J., Matsumoto, K., Pennington, L. D., Winter, M. A., Adrian, M. D., Cole, H. W., Magee, D. E., Phillips, D. L., Rowley, E. R., Short, L. L., Glasebrook, A. L., and Bryant, H. U. (1997) Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene. J. Med. Chem. 40, 146-167.
38. Kost, A. N., Budylin, V. A., Matveeva, E. D., and Sterligov, D. O. (1970) Isomerization of 3-substituted indoles, benzofurans, and benzo[b]thiophenes. Zh. Org. Khim. 6, 1516-1517.
39. Chen, Y., Liu, X., Pisha, E., Constantinou, A. I., Hua, Y., Shen, L., van Breemen, R. B., Elguindi, E. C., Blond, S. Y., Zhang, F., and Bolton, J. L. (2000) A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem. Res. Toxicol. 13, 342-350.